

**REMARKS**


This Preliminary Amendment is being made upon entry of International Application No. PCT/US2004/009909 into the U.S. National Phase of prosecution.

In the specification, a new paragraph has been added to the first line of the specification to include the priority information. An Abstract on a separate sheet is attached as required under 37 CFR 1.72(b).

The claims are 1-11, 16-19, 21-23, 27 and 31, with claims 1, 19, 22 and 31 being independent. Claims 12-16, 20, 24-26, 28-30 and 32 have been cancelled without prejudice or disclaimer. Claim 11 has been amended to include the subject matter of claim 15. Claim 11 has been amended to include the subject matter of claim 15. Claim 16 has been amended to include the subject matter of claim 12. Claim 17 has been amended to include the subject matter of claim 14. Claim 21 has been amended to include the subject matter of claim 27, 28 and 30. Claim 22 has been amended to cancel the definition of a substituents not included in the structure of the compound of claim 22. Claim 27 has been amended to include the subject matter of claim 25. Claim 31 has been amended to include the subject matter of claim 30.

Entry of this amendment into the record is requested.

Respectfully submitted,

  
Kathryn L. Sieburth  
Attorney for Applicants  
Registration No. 40,072

GLAXOSMITHKLINE  
Corporate Intellectual Property UW2220  
P.O. Box 1539  
King of Prussia, PA 19406-0939  
Phone (610) 270-5012  
Facsimile (610) 270-5090

N:\KLS\Cases\PU60173\preliminary amendment.doc